Gastrointestinal Hemorrhage after Concurrent Chemoradiotherapy in Locally Advanced Pancreatic Cancer
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6%) and hemorrhage (25.6%), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65%). The origins of GI hemorrhage were gastric ulcer (37.5%), duodenal ulcer (37.5%), and radiation gastritis (15.0%). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering
Abstract
Background/Aims: While chemoradiotherapy (CRT) is considered to be a reasonable treatment for locally advanced pancreatic cancer (LAPC), there is little information about the associated risk of gastrointestinal (GI) hemorrhage. We investigated the clinical features of GI toxicity after CRT in patients with LAPC and examined the effect of GI hemorrhage on survival. Methods: Patients enrolled in this study had received CRT for pathologically proven LAPC. Their medical records were retrospectively reviewed. Results: A total of 156 patients with LAPC (median age, 65 years; range, 39 to 90 years) who received treatment between August 2005 and March 2009 were included in this study. The most common GI toxicities were ulcer formation (25.6%) and hemorrhage (25.6%), and the most common grade 3 to grade 5 GI toxicity was hemorrhage (65%). The origins of GI hemorrhage were gastric ulcer (37.5%), duodenal ulcer (37.5%), and radiation gastritis (15.0%). The independent risk factor for GI hemorrhage was tumor location in the pancreatic body. The median overall survival of the patients with a GI hemorrhage was 13.8 months (range, 2.8 to 50.8 months) and was not significantly different from that of patients without GI hemorrhage. Conclusions: GI hemorrhage was common in patients with LAPC after CRT. Although GI hemorrhage was controlled with endoscopic hemostasis, preventive measures should be investigated to reduce needless suffering
참고문헌 (20)
- Jemal A, "Cancer statistics, 2009", CA Cancer J Clin, 59, pp.225~249 (2009)
- Winek T, "Prognostic factors for survival after pancreaticoduodenectomy for malignant disease", Am J Surg, 159, pp.454~456 (1990)
- Willett CG, "Locally advanced pancreatic cancer", J Clin Oncol, 23, pp.4538~4544 (2005)
- Hidalgo M, "Pancreatic cancer", N Engl J Med, 362, pp.1605~1617 (2010)
- Shinchi H, "Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer", Int J Radiat Oncol Biol Phys, 53, pp.146~150 (2002)
- Huguet F, "Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies", J Clin Oncol, 25, pp.326~331 (2007)
- Nakachi K, "A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer", Cancer Chemother Pharmacol, 66, pp.527~534 (2010)
- Chauffert B, "Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD", SFRO study, 2008, pp.19, 1592~1599
- Sawaki A, "Clinical impact of radiotherapy for locally advanced pancreatic cancer", J Gastroenterol, 44, pp.1209~1214 (2009)
- DeCosse JJ, "The natural history and management of radiation induced injury of the gastrointestinal tract", Ann Surg, 170, pp.369~384 (1969)
- Sell A, "Acute gastric ulcers induced by radiation", Acta Radiol Ther Phys Biol, 4, pp.289~297 (1966)
- Li CP, "Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study", Int J Radiat Oncol Biol Phys, 57, pp.98~104 (2003)
- Moertel CG, "Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group", Cancer, 48, pp.1705~1710 (1981)
- Boz G, "Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma", Int J Radiat Oncol Biol Phys, 51, pp.736~740 (2001)
- Mehta VK, "Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer", Am J Clin Oncol, 24, pp.155~159 (2001)
- Henry AM, "Chemoradiotherapy for locally advanced pancreatic cancer: a radiotherapy dose escalation and organ motion study", Clin Oncol (R Coll Radiol), 20, pp.541~547 (2008)
- Gastrointestinal Tumor Study Group, "Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone", J Natl Cancer Inst, 80, pp.751~755 (1988)
- Krishnan S, "Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy", Cancer, 110, pp.47~55 (2007)
- Crane CH, "Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?", Int J Radiat Oncol Biol Phys, 52, pp.1293~1302 (2002)
- Huguet F, "Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review", J Clin Oncol, 27, pp.2269~2277 (2009)